Cancer chronomics I. Origins of timed cancer treatment: early marker rhythm-guided individualized chronochemotherapy.
A 21-year old patient who presented in 1973 with a rare and highly malignant ovarian endodermal sinus tumor with spillage into the peritoneal cavity is alive and well today after receiving chronochemotherapy. During the first four courses of treatment, medications were given at different circadian stages. Complete blood counts and marker variables such as mood, vigor, nausea, and temperature were monitored around the clock and analyzed by cosinor to seek times of highest tolerance. Remaining treatment courses were administered at a time corresponding to the patient's best drug tolerance, rather than extrapolating the timing of optimal cyclophosphamide administration from also-implemented parallel laboratory studies on mice. Notwithstanding remaining hurdles in bringing chronochemotherapy to the clinic for routine care, merits of marker rhythm-guided chronotherapy documented in this and other case reports have led to the doubling of the two-year disease-free survival of patients with large perioral tumors in a clinical trial.
Halberg
Franz
F
Halberg Chronobiology Center, University of Minnesota, Minneapolis, MN 55455, USA. halbe001@umn.edu
Prem
Konald
K
Halberg
Francine
F
Norman
Catherine
C
Cornélissen
Germaine
G
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002909:Chronobiology Phenomena; D019454:Chronotherapy / Q000379:methods*; D002940:Circadian Rhythm; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D051379:Mice; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010534:Peritoneal Neoplasms / Q000188:drug therapy; D013997:Time Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents